"Biotech is all about innovation, and we forgot that."

Kleanthis Xanthopoulos, president and CEO of microRNA company Regulus Therapeutics Inc. on the challenges facing the drug development industry

"A quick note to the FDA: Isn't it finally time to make complete response letters public?"

Rodman & Renshaw analyst Simos Simeonidis in a research note on MannKind Corp.'s CRL for inhaled insulin Afrezza

"Otherwise, you're an army of one charging up a hill."

Steve Worland, CEO of Anadys Pharmaceuticals Inc., on the importance of working proactively with investors and shareholders

No Comments